NeuroPace to Participate in Upcoming Healthcare Conferences in September
NeuroPace Second Quarter 2024 Earnings: Beats Expectations
Earnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57
A Quick Look at Today's Ratings for NeuroPace(NPCE.US), With a Forecast Between $8 to $20
Express News | Neuropace Shares Are Trading Lower. The Company Reported Q2 Financial Results. Wells Fargo Lowered Its Price Target on the Stock From $20 to $15
Express News | Cantor Fitzgerald Reiterates Overweight on NeuroPace, Maintains $18 Price Target
NeuroPace Is Maintained at Overweight by Wells Fargo
NeuroPace Analyst Ratings
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15
Earnings Call Summary | NeuroPace(NPCE.US) Q2 2024 Earnings Conference
Express News | Neuropace, Inc. : Wells Fargo Cuts Target Price to $15 From $20
Microelectronic Medical Implants Market Report 2024-2029, With Profiles of Leading Players, Including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro
Express News | Neuropace Inc : JP Morgan Cuts Target Price to $9 From $17
NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript
NeuroPace | 10-Q: Q2 2024 Earnings Report
NeuroPace 2Q Rev $19.3M >NPCE
NeuroPace 2Q Loss/Shr 26c >NPCE
Express News | Neuropace Inc: Increased Full-Year 2024 Revenue Guidance to $76 Mln to $78 Mln
Express News | Neuropace, Inc. Q2 EPS USD -0.26 Vs. IBES Estimate USD -0.3
Express News | Neuropace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance